Monitoring Thyroglobulin in a Sensitive Immunoassay Has Comparable Sensitivity to Recombinant Human TSH-Stimulated Thyroglobulin in Follow-Up of Thyroid Cancer Patients
Open Access
- 1 January 2007
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 92 (1), 82-87
- https://doi.org/10.1210/jc.2006-0993
Abstract
Context: Most thyroglobulin (Tg) assays have a sensitivity of 0.5–1 ng/ml. A minority of patients with undetectable T4-suppressed Tg levels have a recombinant human TSH (rhTSH)-stimulated Tg above 2 ng/ml and identifiable residual disease. Objective: The objective was to determine whether a Tg assay with improved sensitivity could eliminate the need for rhTSH stimulation when baseline Tg is below 0.1 ng/ml. Design: A retrospective study of two academic endocrine practices was conducted. Population: A total of 194 patients undergoing rhTSH stimulation participated in the study. Results: Of the 80 patients with Tg below 0.1 ng/ml, two (2.5%) had rhTSH-stimulated Tg above 2 ng/ml. One other patient with stimulation to 0.3 ng/ml and negative 123I scan had an ultrasound-detected malignant lymph node resected. None had 131I/123I imaging after rhTSH stimulation suggestive of local recurrence or distant metastasis. If T4-suppressed Tg was 0.1–0.5 or 0.6–2.0 ng/ml, rhTSH Tg was above 2 ng/ml in 24.2 and 82.4%, respectively. Conclusions: Patients with differentiated thyroid carcinoma and a T4-suppressed serum Tg below 0.1 ng/ml rarely have a rhTSH-stimulated Tg above 2 ng/ml, and none of these patients had 131I or 123I imaging after rhTSH stimulation suggestive of local recurrence or distant metastasis. We recommend monitoring such patients with a T4-suppressed Tg level and periodic neck ultrasonography. An increase in T4-suppressed serum Tg to a detectable level or the appearance of abnormal lymph nodes by physical or ultrasound exam should prompt further investigation.Keywords
This publication has 15 references indexed in Scilit:
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Recombinant Human Thyrotropin-Stimulated Serum Thyroglobulin Combined with Neck Ultrasonography Has the Highest Sensitivity in Monitoring Differentiated Thyroid CarcinomaJournal of Clinical Endocrinology & Metabolism, 2003
- A Consensus Report of the Role of Serum Thyroglobulin as a Monitoring Method for Low-Risk Patients with Papillary Thyroid CarcinomaJournal of Clinical Endocrinology & Metabolism, 2003
- Is the Serum Thyroglobulin Response to Recombinant Human Thyrotropin Sufficient, by Itself, to Monitor for Residual Thyroid Carcinoma?Journal of Clinical Endocrinology & Metabolism, 2002
- Management of Low-Risk Well-Differentiated Thyroid Cancer Based Only on Thyroglobulin Measurement After Recombinant Human ThyrotropinThyroid®, 2002
- Diagnostic 131-Iodine Whole-Body Scan May Be Avoided in Thyroid Cancer Patients Who Have Undetectable Stimulated Serum Tg Levels After Initial TreatmentJournal of Clinical Endocrinology & Metabolism, 2002
- Clinical Comparison of Whole-Body Radioiodine Scan and Serum Thyroglobulin After Stimulation with Recombinant Human ThyrotropinThyroid®, 2002
- Prediction of Disease Status by Recombinant Human TSH-Stimulated Serum Tg in the Postsurgical Follow-Up of Differentiated Thyroid CarcinomaJournal of Clinical Endocrinology & Metabolism, 2001
- Preparation by Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal Are Comparable for the Detection of Residual Differentiated Thyroid CarcinomaJournal of Clinical Endocrinology & Metabolism, 2001
- Comparison of Administration of Recombinant Human Thyrotropin with Withdrawal of Thyroid Hormone for Radioactive Iodine Scanning in Patients with Thyroid CarcinomaNew England Journal of Medicine, 1997